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Abstract
Background: In our ageing society, valvular heart diseases (VHD) have become an increasing public health
problem. However, the lack of studies describing the impact of these diseases on the outcome of very old subjects
makes it difficult to appreciate their real clinical burden.
Methods: Prospective, observational, population-based cohort study in Belgium. Five hundred fifty six subjects
aged 80 years and older were followed up for 5.1 ± 0.25 years for mortality and 3.0 ± 0.25 years for hospitalization.
Echocardiograms were performed at baseline. The Cumulative Illness Rating Scale (CIRS) was calculated for each
subject.
Results: The prevalence of moderate-to-severe VHD was 17 % (n = 97). Mitral stenosis was more prevalent in
women and an age-dependent increase of the prevalence of severe aortic stenosis was seen. The overall disease
burden was higher in participants with VHD (median CIRS 3 [IQR 3–5] vs 4 [IQR 3–6] (P = 0.008)). Moderate-to-severe
VHD, and more specifically mitral stenosis and aortic stenosis, was found to be an independent predictor of both
all-cause (HR 1.42 (95 % CI 1.04–1.95)) and cardiovascular mortality (HR 2.13 (95 % CI 1.38–3.29)). Moderate-to-severe
VHD was also found to be an independent predictor of the need for a first unplanned hospitalization (HR 1.43
(95 % CI 1.06–1.94)).
Conclusions: A high prevalence of moderate-to-severe VHD was found in the very old. Moderate-to-severe VHD
was identified as an independent risk factor for all-cause and cardiovascular mortality and as well for unplanned
hospitalizations, independent of other structural cardiac abnormalities, ventricular function and major
co-morbidities.
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Background
In the next several decades, the proportion of very old
people living in industrialized countries will dramatically
increase [1]. People aged 80 and older are indeed the
fastest growing age segment in the Western World, and
their numbers will peak by 2050 [2]. This forthcoming
“grey epidemic” will lead to an explosion of chronic
diseases and generate numerous complicated cases with
multiple comorbid conditions.
In this ageing society, the burden of cardiac diseases is
not only rising, but its very nature is also changing. Sev-
eral population-based studies have indeed demonstrated
that the prevalence of systolic dysfunction in the oldest
old is steadily decreasing, whereas that of diastolic dys-
function and valvular heart diseases (VHDs) is increas-
ing [3–6]. Survival effects and age-related changes in
cardiac structure and function most likely explain this
reverse epidemiology [6, 7]. Despite these observations,
data on the clinical burden of VHDs in elderly subjects
are scarce and mostly based on in-hospital series, which
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introduces an important selection bias. Although some
observational studies have suggested that VHDs, and
particularly aortic stenosis, negatively affect the physical
capacity and mental performance of elderly patients [6],
very few of these studies focused on their impact on pa-
tient’s outcome and quality of life. In the absence of rele-
vant outcome data and evidence-based guidelines, the
management of elderly patients with VHDs remains em-
pirical and most often challenging [8]. Consequently,
very old patients presenting with VHDs frequently refuse
or are denied valve surgery, as the risk of cardiac surgery
is often perceived to outweigh any possible clinical bene-
fits [9–11]. Although with the advent of percutaneous
treatments, these patients can nowadays be treated at a
much a lower risk [8], the lack of studies describing the
impact of VHDs on the outcome of very old subjects
makes it difficult to appreciate the real benefits of these
emerging treatments. In this context, the aim of the
present study was to assess the prevalence, distribution
patterns, and outcome consequences of significant
(moderate-to-severe) left-sided VHDs in people aged 80
and older. Based on previous observations, we hypothe-
sized that VHDs were not only highly prevalent but also
beard significant and independent prognostic implica-
tions in very old subjects from the community.
Methods
Study population
The BELFRAIL study is a prospective, observational,
population-based cohort study of subjects aged 80 years
and older in three well-circumscribed areas of Belgium
(Flanders, Brussels and Wallonia). All participants in the
study gave informed consent, and the Biomedical Ethics
Committee of the Université catholique de Louvain
(UCL) in Brussels approved the study. The study design,
methods and characteristics of the cohort were previ-
ously described in detail [12]. Briefly, 29 general practi-
tioner (GP) centers were asked to include patients aged
80 and older. No other inclusion criteria were specified,
and only three exclusion criteria were used: known
severe dementia (mini-mental state examination < 15),
palliative care, and medical emergency, such as acute
onset heart failure or decompensated heart failure.
The BELFRAIL cohort is representative in gender and
age of the elderly living in Belgium [12].
Clinical evaluation
At study entrance, the GPs used a structured question-
naire to capture information on the patients’ medical
history, cardiovascular risk factors, symptoms [13], and
other current medical problems. These data were subse-
quently used to calculate the cumulative illness rating
scale (CIRS) [14, 15], which was used as a multimorbid-
ity index. The GPs were also asked to list the drugs the
patients were taking on a regular basis or as needed.
Drugs were classified according to the Anatomical,
Therapeutic and Chemical (ATC) classification system
(at level 5, which relates to the chemical substance).
Data on relevant cardiovascular medications including
diuretics, potassium-sparing agents, angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, β-
blockers and digitalis were also collected.
The subjects’ performance in basic activities of daily
living (ADL) was assessed [12]. Cognitive functioning
was measured by the Mini-Mental State Examination
(MMSE). Depressive symptoms were measured in those
with MMSE > 18 points by use of the 15-item Geriatric
Depression Scale (GDS-15) [12].
Echocardiography
Echocardiographic data were obtained at the subject’s
home using a commercially available portable system
(CX50, Philips, Andover, Massachusetts, USA). All pa-
tients underwent a comprehensive examination, including
M-mode and 2-dimensional echocardiography, as well as
Doppler examinations, according to the recommendations
of the American Society of Echocardiography and the
European Association of Echocardiography (EAE) [16].
All tests were conducted by a certified cardiologist with
level 3 competence in echocardiography.
The echocardiographic images were blindly analyzed
by 1 or 2 observers with at least 2 years of experience in
reading echocardiographic studies. All measurements
were performed off-line using the XCelera software
(Philips, Andover, Massachusetts, USA). In patients with
poor quality images, all measurements were performed
by the 2 observers and the averaged values were re-
ported. In patients with good image quality, data were
analyzed by only one single observer. To ensure ad-
equate reproducibility, inter- and intra-observer variabil-
ity was evaluated on a random sample of good quality
echocardiograms. Intraclass correlation coefficients were
always > 0.90.
LV volumes and LVEF were calculated by use of the
biplane Simpson method, whereas LV mass was calcu-
lated according to Devereux et al [16]. Left atrial (LA)
volume was measured using the biplane area-length for-
mula. Systolic pulmonary artery pressure was considered
to be equal to the systolic transtricuspid pressure gradi-
ent as calculated by use of the modified Bernoulli equa-
tion. No attempt was made to estimate right atrial
pressure.
The function of the mitral, aortic and tricuspid valves
was evaluated by use of standard continuous-wave,
pulsed-wave and color Doppler echocardiograph, as
recommended by the EAE [17–19]. In patients with
aortic stenosis, stenosis severity was quantitated by
use of the peak transaortic jet velocity, the mean
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transaortic gradient and the aortic valve area (con-
tinuity equation). In patients with mitral stenosis,
stenosis severity was quantitated by use of the mean
transmitral pressure gradient and the mitral valve area
(direct planimetry or pressure half-time). The severity
of aortic and mitral regurgitations was assessed semi-
quantitatively on a scale of 1+ to 4+ by an integrated
approach that included the size of the regurgitant jet
in the receiving chamber, the proximal regurgitant jet
width, the size of the proximal convergence zone and,
when available, the regurgitant volume and the effect-
ive regurgitant orifice area. Mild, moderate and severe
degrees of valve dysfunctions were graded as recom-
mended by the EAE guidelines [18, 19].
Outcome measures
Two detailed follow-up questionnaires were filled in
by the participating GPs after 1.4 ± 0.3 years and after
3.0 ± 0.3 years. The questionnaires included questions
on mortality, cause of death and unplanned hospitalization.
Mortality and cause of death were also recorded by the GPs
5.1 ± 0.3 years after baseline. The causes of death were di-
vided into cardiovascular and non-cardiovascular causes,
according to the GPs’ assessment and the subsequent re-
view by 2 independent researchers blinded to all clinical
data (BV and JD). The current study used all-cause mortal-
ity, cardiovascular mortality and first, all-cause, unplanned
hospitalizations for > 24 h as outcome measures.
Data analysis
The data analysis was performed using SPSS 20.0 for
Windows (SPSS Inc., Chicago, IL, USA). Continuous
variables are reported as mean ± one standard deviation
(SD) or median and inter-quartile range (IQR). Categor-
ical variables are reported as numbers and frequencies.
Comparisons between different categories of subjects were
performed using a one-way ANOVA, the Mann-Whitney
U test (nonparametric data) for unpaired data or the
Jonckheere-Terpstra test (trend test), where appropriate.
Survival curves were computed using the Kaplan-
Meier method and compared using the log-rank Chi
square test. Determination of the factors independently
associated with outcome was performed by use of a
Cox's proportional-hazards survival analysis. For this
purpose, all clinical, angiographic, and echocardio-
graphic variables with p < 0.10 in the univariable analysis
were proposed for inclusion into a multivariable Cox’s
proportional-hazards survival model. In order to avoid
multicollinearity, the correlation coefficients between all
covariates were calculated. In case of multicollinearity
(r-value >0.80), only one of the two covariables was con-
sidered in the multivariable model. Variable selection
was performed using a stepwise, forward conditional se-
lection procedure using the maximum partial likelihood
ratio chi-square statistic (χ2 test) to enter (<0.05 level) or
to remove (>0.05 level) a covariable into the model.
Variables were entered until no F-to-enter statistics were
significant at the 5 % level and until the mean squared
error reached a minimum.
Results
Baseline clinical, hemodynamic and echocardiographic
characteristics
Echocardiograms were obtained in 556 subjects (98 %),
aged 84.7 ± 3.6 years, of whom 41 % were older than
85 and 9 % older than 90 years. The prevalence of
moderate-to-severe VHD was found to be 17 %, and
was similar in men (16 %) and women (18 %). Higher
rates of MS were noted in women than in men (4.6
vs 1.5 %, p = 0.026). The prevalence of the other VHD
was quite similar between men and women (13 vs
15 % for AS, 1.5 vs 1.7 % vs AR and 0.5 vs 0.9 % for
MR). A significant trend in age-related prevalence
was found for aortic stenosis, with a significantly in-
creased prevalence of severe stenosis and a signifi-
cantly decreased prevalence of mild stenosis in the
very old (Table 1).
No significant differences in baseline characteristics
were noted among subjects without any VHD and those
with mild VHD. By contrast, higher rates of decompen-
sated heart failure, stroke and chronic atrial fibrillation
were noted in subjects with moderate-to-severe VHD as
compared to those with no or mild VHD. The preva-
lence of heart failure related symptoms, such as dyspnea
and peripheral edema were also higher among subjects
with moderate-to-severe VHD than among those with-
out (Table 2). Patients with moderate-to-severe VHD ex-
hibited higher CIRS and GDS-15 scores, and lower ADL
scores than those without. As shown in Table 3, patients
with moderate-to-severe VHD exhibited larger LAs, LV
masses, E/e’ ratios and E/A ratios, as well as shorter de-
celeration (DT) and isovolumic relaxation times than
those without.
Clinical outcomes
Follow-up was 100 % complete. After an average follow-
up time of 5.1 ± 0.3 years, there were 236 deaths (42 %),
of which 102 (43 %) were of cardiovascular origin.
Among the 97 subjects with moderate-to-severe VHD,
57 (59 %) died, of which 33 (58 %) died of cardiovascular
causes. Among the subjects with VHD and systolic dys-
function, 19 (59 %) died, of whom 8 (42 %) from cardio-
vascular causes. As shown in Fig. 1, 5-year overall and
cardiovascular survival was significantly lower in sub-
jects with moderate-to-severe VHD than in those with
no or mild VHD.
After an average follow-up time of 3.0 ± 0.3 years, 278
participants (50 %) needed hospitalization. Hospitalization
Rezzoug et al. BMC Cardiovascular Disorders  (2016) 16:7 Page 3 of 10
data were missing for only one participant. As shown in
Fig. 1c, the freedom from a first unplanned hospitalization
was better in patients with no or mild VHD than in those
with moderate-to-severe VHD.
Predictors of all-cause and cardiovascular mortality
As show in Table 4, the multivariable Cox’s regression
analysis identified age, moderate-to-severe VHD, CIRS,
severe dyspnea, systolic dysfunction and LV hypertrophy
as independent predictors of all-cause mortality. A dose-
response effect was found for LV mass index (adjusted
HR: 1.01, 95 %-CI [1.00–1.01], p = 0.003) but not for LV
ejection fraction. No relation was found with parameters
of diastolic dysfunction.
Moderate-to-severe VHD was also identified as an
independent predictor of cardiovascular mortality (ad-
justed HR: 2.13; 95 %-CI [1.38–3.29]), together with age,
CIRS, LV hypertrophy and severe dyspnea (Table 4). A
dose-response effect was found for both LV hypertrophy
(adjusted HR: 1.01; 95 %-CI [1.00–1.02], p = 0.029).
Diastolic parameters did not show any relationship with
cardiovascular mortality.
Predictors of first unplanned hospitalizations
Moderate-to-severe VHD, together with the smoking
status, CIRS, and severe dyspnea, was found to be inde-
pendently associated with the need for a first unplanned
hospitalization.
The relationships between moderate-to-severe VHD
and all-cause mortality, cardiovascular mortality and the
need for a first unplanned hospitalization did not change
when echocardiographic parameters were entered as di-
chotomous or continuous variables, nor when the CIRS
was replaced by individual morbidities.
Discussion
Studies investigating the prevalence of VHDs in elderly
subjects are rather scarce and often based on in-hospital
series [4, 20–22]. Studies describing the clinical impact
and outcome consequences of VHDs in very old subjects
are even fewer [22], making it difficult to appreciate
their real burden in our ageing societies. The current
study is the first to investigate the prevalence, clinical
impact and outcome consequences of VHDs in a large
population-based sample of subjects aged 80 and older.
Our results can be summarized as follows:
– The prevalence of moderate-to-severe VHD in very
old subjects is around 17 %, and is similar in men
and women.
– There is a significant age-related increase in both
the prevalence and the severity of aortic stenosis.
– Higher rates of heart failure, atrial fibrillation
and stroke were found in subjects with
moderate-to-severe VHD than in those without.
Accordingly, physical activity and cognitive
functioning was negatively affected in patients
with moderate-to-severe VHD.
– The presence of moderate-to-severe VHD
independently increases overall and cardiovascular
mortality risks, as well as the need for unplanned
hospitalizations.
Table 1 Prevalence of valvular heart disease
80–84 years 85–89 years ≥90 years p for trenda
Participants, n 323 183 50
Male, n (%) 125 (39 %) 68 (37 %) 13 (27 %)
Mitral stenosis, n (%) 10 (53 %) 6 (3 %) 3 (6 %)
Mild, n (%) 5 (2 %) 3 (2 %) 1 (2 %) 0.85
Moderate, n (%) 4 (1 %) 3 (2 %) 2 (4 %) 0.28
Severe, n (%) 1 (0.3 %) 0 (0 %) 0 (0 %) 0.41
Mitral regurgitation, n (%) 236 (73 %) 140 (77 %) 39 (78 %)
Mild, n (%) 234 (72 %) 138 (75 %) 39 (78 %) 0.32
Moderate, n (%) 2 (1 %) 2 (1 %) 0 (0 %) 0.89
Aortic stenosis, n (%) 63 (20 %) 45 (25 %) 19 (38 %)
Mild, n (%) 27 (8 %) 7 (4 %) 1 (2 %) 0.016
Moderate, n (%) 24 (7 %) 15 (8 %) 9 (18 %) 0.10
Severe, n (%) 12 (4 %) 11 (6 %) 9 (18 %) 0.002
Aortic regurgitation, n (%) 118 (37 %) 72 (39 %) 25 (50 %)
Mild, n (%) 113 (35.4) 69 (37.9) 24 (48.0) 0.15
Moderate, n (%) 5 (1.6) 3 (1.6) 1 (2.0) 0.85
aJonckheere-Terpstra Test
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Prevalence of VHD in very old subjects
The BELFRAIL study is one of the largest prospective
observational studies performed so far on the prevalence
of VHD in very old subjects. The salient finding of this
study is that the prevalence of moderate-to-severe VHD
in subjects aged 80 and older is quite high, in the range
of 16−18 %. Moderate-to-severe AS was by far the most
frequently encountered VHD (14 % of very old subjects),
followed by moderate-to-severe degenerative MS (1.7 %),
moderate AR (1.6 %) and finally moderate MR (0.7 %).
Table 2 Clinical characteristics of the study population
No VHD
(n = 92)
Mild VHD
(n = 367)
Moderate-to-severe VHD
(n = 97)
p value
Socio-demographic characteristics
Male, n (%) 38 (41 %) 135 (37 %) 33 (34 %) <0.001
Age, (years) 84.1 ± 2.9 84.6 ± 3.6 86.3 ± 4.3 0.58
Coronary risk factors and multimorbidity
Smoking (current or ex), n (%) 31 (34 %) 122 (33 %) 22 (23 %) 0.11
Hypertension, n (%) 60 (66 %) 258 (70 %) 72 (74 %) 0.46
Dyslipidemia, n (%) 40 (45 %) 165 (46 %) 37 (39 %) 0.46
Type 2 diabetes, n (%) 21 (23 %) 62 (17 %) 19 (20 %) 0.38
CIRS, median (IQR) 4 (3–5) 3 (3–5) 4 (3–6) 0.008
Prior history
Myocardial infarction, n (%) 17 (19 %) 35 (10 %) 8 (8 %) 0.029
TIA or stroke, n (%) 15 (16 %) 57 (16 %) 29 (30 %) 0.025
COPD, n (%) 13 (12 %) 40 (11 %) 10 (10 %) 0.79
Peripheral arterial disease, n (%) 10 (11 %) 29 (8 %) 11 (11 %) 0.45
CABG, n (%) 8 (9 %) 20 (5 %) 8 (8 %) 0.39
PCI, n (%) 12 (13 %) 30 (8 %) 5 (5 %) 0.13
Valvular surgery, n (%) 2 (2 %) 15 (4 %) 2 (2 %) 0.48
Heart failure, n (%) 8 (9 %) 36 (10 %) 16 (16 %) 0.14
Chronic atrial fibrillation, n (%) 4 (4 %) 34 (9 %) 19 (20 %) 0.002
Pacemaker, n (%) 5 (6 %) 21 (6 %) 5 (5 %) 0.97
Symptoms
Angina pectoris, n (%) 11 (12 %) 58 (16 %) 21 (22 %) 0.20
Dyspnea≥ 3a, n (%) 22 (24 %) 101 (28 %) 42 (43 %) 0.005
Peripheral edema, n (%) 31 (34 %) 115 (31 %) 42 (43 %) 0.090
Fatigue, n (%) 17 (19 %) 75 (21 %) 22 (23 %) 0.80
Cardiac medications
Diuretics, n (%) 45 (49 %) 162 (44 %) 54 (56 %) 0.12
Potassium-sparing agents, n (%) 17 (18 %) 53 (14 %) 17 (18 %) 0.54
ACE inhibitors, n (%) 20 (22 %) 123 (28 %) 29 (30 %) 0.39
ARBs, n (%) 18 (20 %) 51 (14 %) 17 (18 %) 0.34
ß-blockers, n (%) 28 (30 %) 161 (44 %) 46 (47 %) 0.035
Digitalis, n (%) 0 (0 %) 11 (3 %) 11 (11 %) <0.001
Physical activity and cognitive functioning
ADL, median (IQR) 25 (21–27) 25 (21–28) 23 (17–27) <0.001
MMSE, median (IQR) 28 (26–29) 28 (26–29) 28 (25–29) 0.36
GDS-15, median (IQR) 2 (1–4) 2 (1–4) 3 (2–5) 0.033
aaccording to the Medical Research Council dyspnea scale. ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CABG coronary artery bypass
graft surgery, CIRS cumulative illness rating scale, COPD chronic obstructive pulmonary disease, IQR interquartile range, PCI percutaneous coronary intervention,
TIA transient ischemic attack
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MS was more prevalent in women and an age-
dependent increase in the prevalence and severity of AS
was observed.
Few previous studies have investigated the prevalence
of VHD in elderly subjects. Although these studies dem-
onstrated an age-dependent increase in the prevalence
of VHD in the ageing population, very little data are
available concerning VHD prevalence among very old
subjects, i.e. those aged 80 years and older. By using data
from 3 large north-American population-based studies
[23–25] as well as from the Olmsted county community
study, Nkomo et al. reported a prevalence of moderate-
to-severe VHD in Americans aged 75 years and older of
11.7 to 13.2 % [4]. Interestingly, most of their patients
presented with moderate-to-severe MR (9.3 % in the
population-based studies, 7.1 % in the Olmsted County
community study) whereas fewer patients presented with
moderate-to-severe AS (2.8 % in the population-based
studies, 4.6 % in in the Olmsted County community
study). Although the results of our study are roughly in
line with those of Nkomo’s study, they nonetheless differ
with regard to the relative prevalence of MR and AS,
MR being more prevalent in these earlier studies than in
ours. Our results also differ from those of the Leyden 85
+ study, in which the prevalence of moderate-to-severe
VHD among subjects aged 90 and older was found to be
close to 50 %, the majority of the subjects presenting
with moderate to severe MR, and only 6 % with
moderate-to-severe AS [22]. The reasons for these dif-
ferences are unclear but may be related to the methods
used to assess of MR severity. Most previous studies,
including that from Nkomo et al., used the semi-
quantitative method described by Helmcke et al [26]
to make this assessment. While this approach works
reasonably well in patients with central jets, it is no-
toriously inaccurate in those with impinging wall jets
due to mitral valve prolapse [27]. In the present
study, we used an integrated approach that included
both qualitative and quantitative parameters, in order
to minimize the natural tendency of echocardio-
graphic methods to overestimate the true severity of
MR [28].
Clinical burden of VHD in very old subjects
Another important objective of our study was to in-
vestigate the clinical and echocardiographic character-
istics of very old subjects presenting with VHD. Our
findings indicate that patients with moderate-to-severe
VHD more often present with heart failure symptoms,
such as dyspnea or peripheral edema; more frequently
have a prior history of heart failure and stroke; and more
frequently present with atrial fibrillation. This negatively
Table 3 Echocardiographic characteristics of the study population
No VHD
(n = 92)
Mild VHD
(n = 367)
Moderate-to-severe VHD
(n = 97)
p value
LV morphology and function
LVEF (%) 55 ± 3 55 ± 5 55 ± 3 0.60
LVEF < 50 %, n (%) 4 (4 %) 26 (7 %) 2 (2 %) 0.14
LV mass (g/m2) 86 ± 21 92 ± 23 98 ± 27 0.002
LVH, n (%) 10 (11 %) 57 (16 %) 18 (19 %) 0.33
Indexed LAV (mL/m2) 30 ± 9 32 ± 10 39 ± 12 <0.001
Indexed LAV > 34 mL/m2, n (%) 23 (25 %) 145 (40 %) 62 (65 %) <0.001
Stroke volume (mL/beat) 68 ± 19 70 ± 16 68 ± 14 0.48
RWMA, n (%) 13 (14 %) 43 (12 %) 7 (7 %) 0.30
LV diastolic filling
E/A ratio 0.87 ± 0.44 0.92 ± 0.48 1.07 ± 0.58 0.027
E/A ratio≥ 1.5, n (%) 6 (7 %) 31 (9 %) 14 (19 %) 0.013
E/e’ ratio 10.7 ± 3.1 11.6 ± 4.0 13.5 ± 4.2 <0.001
E/e’ ratio≥ 13, n (%) 23 (25 %) 102 (28 %) 41 (53 %) <0.001
Deceleration time (ms) 178 ± 41 178 ± 44 174 ± 51 0.74
Deceleration time < 160 ms, n (%) 29 (32 %) 115 (32 %) 35 (48 %) 0.028
Vp (cm/s) 58 ± 17 56 ± 16 52 ± 22 0.12
Vp < 45 cm/s, n (%) 23 (25 %) 114 (32 %) 35 (48 %) 0.006
A atrial transmitral peak velocity, E early transmitral peak velocity, e’ early peak mitral annular velocity, LAV left atrial volume, LVEF left ventricular ejection fraction,
LVH left ventricular hypertrophy (LV mass index >109 g/m2 in women and >132 g/m2 in men.), RWMA regional wall motion abnormalities, Vp velocity of
inflow propagation
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affected their physical activity and cognitive functioning as
measured by the ADL and GDS-15 scores. They were also
more likely to exhibit increased LA volume and LV mass
and to demonstrate echocardiographic features associated
with altered LV diastolic properties and elevated filling
pressures.
Our data also indicate that the VHD detected in our
study were not simply benign imaging observations but
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Fig. 1 Kaplan Meier survival curves for overall survival (panel a), cardiovascular survival (panel b) and freedom from a first unplanned
hospitalization (panel c) in patients with no (solid lines), mild (dotted-dashed lines) and moderate-to-severe (dashed lines), mild and without (solid
lines) VHD. Risk of mortality and hospitalization based on the presence of valvular heart disease
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had profound outcome consequences, as they were asso-
ciated with a 40 % increase in adjusted overall mortality
and a 2.1-fold excess in adjusted cardiovascular mortal-
ity. Patients with moderate-to-severe VHD were also
hospitalized more frequently than patients without. Our
observations confirm and extend those made by Nkomo
et al. as they demonstrate that in elderly patients as well,
moderate-to-severe VHDs are a major and independ-
ent determinant of outcome. Our results also concur
with those of studies that specifically addressed the
impact of aortic stenosis on the outcome of elderly
patients [29, 30].
The excess risk associated with VHD stresses the im-
portance of increasing the awareness of the medical
community on the dismal outcome consequences of
VHDs and on the need to detect them early. Early detec-
tion of VHD, before the onset of symptoms and at a
time when patients are still sufficiently fit to be proposed
surgical valve replacement is probably key to improving
their prognosis. Nkomo et al. have indeed shown that in
the community, VHDs are frequently underdiagnosed,
owing probably to the need for echocardiography to be
clinically indicated before diagnosis is made [4]. Whereas
delaying diagnosis likely has little impact on outcome in
younger individuals, it exposes elderly patients to be de-
nied appropriate treatment because of their advanced age.
The EuroHeart survey has indeed clearly demonstrated
that old patients are frequently denied interventions des-
pite unequivocal guideline-based indications, because of
their advanced age [10, 11].
Table 4 Uni- and multivariable predictors of outcome
Univariable Multivariable
HR 95 % CI p value HR 95 % CI p value
All-cause mortality
Age (year) 1.10 1.07–1.14 <0.001 1.09 1.05–1.12 <0.001
Dyspnea ≥3 2.29 1.77–2.97 <0.001 1.81 1.37–2.39 <0.001
CIRS (per point increase) 1.21 1.12–1.30 <0.001 1.11 1.03–1.21 0.007
Moderate-to-severe VHD 1.91 1.42–2.58 <0.001 1.42 1.04–1.95 0.029
Moderate-to-severe AS 1.96 1.42–2.70 <0.001
LAVI ≥34 mL/m2 1.58 1.22–2.04 0.001
LV hypertrophy 1.01 1.00–1.01 0.004 1.01 1.00–1.01 0.020
Moderate-to-severe MS 2.30 1.08–4.88 0.030
LVEF ≤50 % 1.63 1.02–2.61 0.040 1.66 1.03–2.67 0.037
Dyslipidemia 0.78 0.60–1.01 0.063
Cardiovascular mortality
Age (year) 1.09 1.04–1.14 <0.001 1.06 1.01–1.11 0.014
CIRS (per point increase) 1.23 1.10–1.37 <0.001
Dyspnea ≥3 3.06 2.07–4.53 <0.001 2.68 1.80–3.98 <0.001
Moderate-to-severe VHD 2.88 1.90–4.37 <0.001 2.13 1.38–3.29 0.001
Moderate-to-severe AS 3.06 1.99–4.72 <0.001
Moderate-to-severe MS 4.65 2.03–10.63 <0.001
LAVI ≥34 mL/m2 1.87 1.27–2.77 0.002
LV hypertrophy 1.01 1.00–1.02 0.029 1.01 1.00–1.01 0.087
First unplanned Hospitalization
Smoker (current or ex) 1.60 1.25–2.04 <0.001 1.69 1.32–2.16 <0.001
CIRS (per point increase) 1.20 1.13–1.29 <0.001 1.15 1.07–1.23 <0.001
Dyspnea ≥3 1.81 1.42–2.31 <0.001 1.50 1.16–1.94 0.002
Moderate-to-severe AS 1.71 1.25–2.33 0.001
LAVI ≥34 mL/m2 1.37 1.08–1.74 0.009
Moderate-to-severe VHD 1.51 1.13–2.03 0.006 1.43 1.06–1.94 0.021
Age (year) 1.03 1.00–1.06 0.041
AS aortic stenosis, CI confidence interval, CIRS cumulative illness rating scale, HR hazard ratio, LAVI left atrial volume index, LVEF left ventricular ejection fraction,
MS mitral stenosis, VHD valvular heart disease
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Study limitations
This study has limitations that should be acknowledged.
First, although many factors potentially associated with
VHDs were considered, we cannot exclude the possibil-
ity that some yet unknown confounders contributed to
our results. Second, comorbidities may have been under-
diagnosed, as their identification relied only on the infor-
mation gathered by the general practitioner.
Conclusions
In this large representative population-based sample of
subjects aged 80 and older a high prevalence of VHD
was found. Patients with VHD more frequently pre-
sented with heart failure symptoms, atrial fibrillation
and stroke than those without. They were also found to
be at higher risk for all-cause and cardiovascular mortal-
ity as well as unplanned hospitalizations.
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